Conventus Orthopaedics pulls in $20M to commercialize fracture repair in upper extremity

Conventus nets $20M for fracture-treating implants (Fierce Biotech)
Minnesota’s Conventus Orthopaedics raised $20 million in equity that will expand commercialization of its fracture-repairing implants as well as develop the technology for other indications.
The company’s Cage line of products are FDA-cleared for the treatment of shoulder, elbow and wrist fractures. Conventus earned its latest clearance in 2015, for the surgical repair of fractures in the proximal humerus (shoulder), and the financing will go toward commercializing the product for this indication.
The device is a self-expandin...